SCHEMBL1187044

SCHEMBL1187044

CC(C)c1cccc(NC(=O)Nc2ccc3c(c2)CCN(C(=O)OC(C)(C)C)C3)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.55
▸ NR1H2 P55055 1/20 0.49
▸ NPC1 O15118 6/20 0.48
▸ RAB9A P51151 6/20 0.48
▸ PIK3CA P42336 1/20 0.48
▸ MTOR P42345 1/20 0.48
▸ MAPT P10636 2/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ NAMPT P43490 3/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ TRPV1 Q8NER1 1/20 0.43
▸ KCNA1 Q09470 1/20 0.42
▸ KCNAB1 Q14722 1/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3407075 0.91 ESR2 (0.61) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL1188540 0.88 ESR2 (0.62) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL1188505 0.87 ESR2 (0.54) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL1188304 0.87 ESR2 (0.58) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL1188717 0.86 ESR2 (0.57) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL1189027 0.86 ESR2 (0.57) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL1188325 0.85 NPC1 (0.61) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL1188104 0.85 ESR2 (0.61) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL1188340 0.85 ESR2 (0.53) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL1187768 0.85 ESR2 (0.53) ESR2NR1H2NPC1RAB9APIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735425-B2 Tetrahydroisoquinoline derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-27 — — US disclosed
EP-2256105-B1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-12-04 — — EP disclosed
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-10 — — US disclosed
EP-2256105-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-12-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DGAT1, DGAT2, DLAT ESR2 3292/4885NR1H2 306/4885NPC1 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback